About AnaptysBio

Founded in 2005, AnaptysBio is a privately-held therapeutic antibody company and the leader in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies.  SHM is the body’s natural process for generating potent antibodies to fight disease. 

The Company’s SHM-XEL™ platform couples SHM with other leading-edge technologies to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired binding and specificity properties for  various applications. AnaptysBio has established broad intellectual property around the use of SHM, and is currently building a pipeline of novel therapeutic antibody product candidates.